E
Exobiosphere
Platform leveraging microgravity to accelerate drug discovery and develop novel therapeutics for improved human health
About Exobiosphere
Exobiosphere is a Luxembourg space-biotech company founded in 2024 that advances drug discovery and biomedical research in microgravity. Led by CEO and co-founder Kyle Acierno, its orbital high-throughput screening platform can run thousands of automated experiments per mission for pharmaceutical, biotech and research partners seeking biological insights that are difficult to obtain on Earth. The company also maintains a presence in Los Angeles. Disclosed financing and awards include early backing from Cedars-Sinai Technology Ventures tied to a space-biomedicine collaboration, a $1 million Meet The Drapers award, CASSINI accelerator support, and a €1 million Jeune Entreprise Innovante (JEI) grant from Luxembourg’s Ministry of the Economy in August 2026 to strengthen operations, commercial expansion and scale-up of the screening platform. Sources: Exobiosphere 11 Aug 2026; Cedars-Sinai; Le Quotidien.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Esch-sur-Alzette, Luxembourg
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 88.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Space Tech, Biotech and Pharma, In-Space Research, In-Space Operations, Space Upstream, Techbio, Space DT
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Aug 2026 | $1.1M | — | Ministry of the Economy Luxembourg | ↗ |
| SUPPORT PROGRAM✓Other financing | May 2026 | $83K | — | Cassini Business Accelerator · EUSPA · CASSINI Initiative | ↗ |
Growth signals
Latest recorded traffic for Exobiosphere is 380 monthly website visits, down 77.6% over the last three months. Exobiosphere's team grew 68.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Expansion Ventures
SpaceData
Expon Capital
Boryung Pharmaceutical
Meet The Drapers
Ministry of the Economy Luxembourg
Series A1 investor entered at this stage
Cedars-Sinai Technology Ventures
Other known investors7 additional known investors
CASSINI Initiative
EUSPA
Cassini Business Accelerator
Bioincubator
House of Biohealth
Luxinnovation
Tim Draper
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exobiosphere on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exobiosphere’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.